Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy

Cerebrospinal Fluid Leakage Clinical Trial

Official title:

A Prospective, Open, Multi-center, Single-arm Study of the Performance and Safety of I-020805 in the Prevention of Cerebrospinal Fluid Leakage Following Elective Cranial Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01295619
• Other study ID #: CS I-020805/01
• Status: Completed
• Phase: N/A
• First received: February 9, 2011
• Last updated: November 25, 2016
• Start date: February 2011
• Est. completion date: December 2011

Study information

• Verified date: November 2016
• Source: Kuros Biosurgery AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective study to evaluate the performance and safety of a new medical device used in case of cerebrospinal fluid (CSF) leakage after an elective cranial surgery.

Description:

Patients who consented to participate in the trial and fulfilled the preoperative inclusion and exclusion criteria underwent screening prior to surgical treatment. After dural suturing, if patients met the intra operative inclusion and exclusion criteria, they received I-020805. If necessary, autologous grafts were to be used to augment dural closure.

I-020805 was delivered from a double syringe applicator that creates a fine layer over the dura. This layer quickly sets within seconds to form a watertight seal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Pre-operative

• Male or female of 18 years old or over

• Elective cranial procedure entailing a dural incision of at least 2 cm in length

• Requires a procedure involving surgical wound classification Class I/Clean

• Signed informed consent form

• Negative pregnancy test at screening for women of childbearing potential and agreeing to use an acceptable birth control method or abstinence until 90 days post-surgery

Intra-operative

• Surgical wound classification Class I/Clean

• Dural margin from bony edges of at least 3 mm throughout

• Spontaneous expression of CSF assessed visually or a CSF leakage upon Valsalva maneuver

Exclusion Criteria:

Pre-operative

• Cranial procedure requiring translabyrinthine, transoral and/or any procedure penetrating the air sinus or mastoid air cells

• Presence of symptomatic hydrocephalus

• Pre-existing external ventricular drainage or lumbar CSF drain

• Radiotherapy in the planned surgical region which ended within 3 months prior to planned surgery

• Presence of systemic infection

• Known history of hemophilia or other clinically significant coagulopathy

• Known oral anticoagulant use

• Pregnancy or breast feeding

• Known allergy to any components of I-020805

• Previous participation in this trial or any investigational drug or device study within 30 day of screening

• Known clinically significant organ or systemic diseases

• Known or suspected non-compliance with trial procedures

Intra-operative

• Patient not meeting the pre-operative eligibility criteria

• Not able to tolerate a Valsalva maneuver

• Gap of more than 2 mm remaining after primary closure of dura

• Use of synthetic or non-autologous duraplasty material

Related Conditions & MeSH terms

• Cerebrospinal Fluid Leak
• Cerebrospinal Fluid Leakage

Intervention

Device:
• I-020805
A thin layer of I-020805 applied up to two times on the sutured dura mater

Locations

Country	Name	City	State
Germany	Charite Universitätsmedizin (01)	Berlin
Hungary	Orszagos Idegtudomanyi Intezet (11)	Budapest
Hungary	Debreceni Tudomanyegyetem (12)	Debrecen
Hungary	Szegedi Tudomanyegyetem (10)	Szeged

Sponsors (1)

Lead Sponsor	Collaborator
Kuros Biosurgery AG

Countries where clinical trial is conducted

Germany,  Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance of I-020805 in prevention of CSF leakage		Intraoperative on the day of sugery
Secondary	Incidence of CSF leakage		Within 7 days after surgery or prior to discharge
Secondary	CSF leakage or pseudomeningocele related surgical intervention		Within 90 days following surgery
Secondary	CSF leakage confirmed by clinical evaluation or diagnostic testing		Within 90 days following surgery
Secondary	Surgical infection and unexpected neurological signs		Post-operative and within 7 days and 90 following surgery
Secondary	Wound healing impairment		Throughout study up to 90 days following surgery
Secondary	Incidence of all and treatment emergent adverse events		Throughout study up to 90 days following surgery